CervoMed to Present New Neflamapimod Data, Including First 80mg BID Clinical Results, at AAIC 2026
CRVO sits 69% above its 52-week low of $2.13 on light trading volume (0.1× avg).
Summary
CervoMed will present five scientific posters at the Alzheimer's Association International Conference (AAIC) 2026, with four focusing on its lead drug candidate, neflamapimod, for Dementia with Lewy Bodies (DLB). The presentations will include new exploratory analyses from the Phase 2 RewinD-LB trial and the first clinical data for the 80mg BID dose of neflamapimod. This follows previous positive Phase 2b data and the finalization of Phase 3 trial design for neflamapimod. For this clinical-stage biotech, showcasing detailed data at a major conference is important for validating its lead asset and maintaining investor interest, especially after recent financing activities.
At the time of this announcement, CRVO was trading at $3.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48M. The 52-week trading range was $2.13 to $13.13. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.